Live Feeds
● LIVE Updated 2h ago · 9 sources tracked

Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race

Roche has entered into a licensing agreement with China's Rona Therapeutics for an obesity therapy, with the deal potentially worth up to $1.2 billion. The partnership grants Roche access to Rona's genetic obesity approach, specifically targeting ALK7. This move expands Roche's presence in the emerging obesity treatment market.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Roche's deal with Rona Therapeutics is worth up to $1.2 billion.
  • ✓ The partnership targets ALK7 for obesity treatment.
  • ✓ Roche has made seven deals in China this year.
🛡️ Source Corroboration: 9 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Roche's agreement with Rona Therapeutics marks its seventh deal in China this year, highlighting the company's aggressive expansion in the region.

Live updates

  1. Roche inks $1.2B deal with China's Rona for obesity therapy

    Roche has entered into a licensing agreement with China's Rona Therapeutics for an obesity therapy, with the deal potentially worth up to $1.2 billion. The partnership grants Roche access to Rona's genetic obesity approach, specifically targeting ALK7. This move expands Roche's presence in the emerging obesity treatment market.

    Why it matters

    The deal is part of Roche's strategy to bolster its research and development footprint in obesity treatment. Obesity is a growing health concern globally, and pharmaceutical companies are actively seeking innovative solutions. The partnership with Rona Therapeutics adds to Roche's recent string of collaborations, particularly in China.

    What is confirmed

    • Roche's deal with Rona Therapeutics is worth up to $1.2 billion.
    • The partnership targets ALK7 for obesity treatment.
    • Roche has made seven deals in China this year.

    What to watch next

    • Roche's progress in developing obesity treatments
    • Regulatory approvals for the ALK7 therapy
    • Roche's future collaborations in the obesity treatment space
    Sources used for this update (9)
    1. Fierce Biotech — Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
    2. WSJ — Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal
    3. Reuters — Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
    4. BioSpace — Roche expands obesity R&D footprint with Rona deal worth $1B+
    5. Endpoints News — Roche's seventh China deal this year is a $1.2B obesity pact with an RNAi biotech
    6. www.biospace.com — Roche expands obesity R&D footprint with Rona deal worth $1B+
    7. finance.yahoo.com — Roche extends China deal streak with $1B pact for RNAi ...
    8. www.finanznachrichten.de — ROCHE HOLDING AG PS
    9. www.myasset.com — Sector News & Data
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community